Table 1.

Patient sex demographics in FAERS drug cohorts.

Sex	Alendronate	Zoledronate	Risedronate	Ibandronate	Denosumab	Teriparatide
Female	6,540	7,997	1,051	3,431	13,242	40,821
Male	757	1,145	57	199	1,759	3,974
Unreported	524	225	60	97	811	257
Female frequency (%)	83.6	85.3	89.9	92.1	83.7	90.6
Male frequency (%)	9.6	12.2	4.8	5.3	11.1	8.8